Skip to main content
. Author manuscript; available in PMC: 2016 Aug 15.
Published in final edited form as: Clin Cancer Res. 2015 May 12;21(16):3771–3782. doi: 10.1158/1078-0432.CCR-14-3145

Figure 6. CpG-STAT3 siRNA blocks arginase expression and inhibits functions of granulocytic MDSCs.

Figure 6

(A, B) STAT3 targeting using CpG-siRNA strategy inhibits arginase expression and activity in granulocytic MDSCs. Levels of arginase mRNA (A) and enzymatic activity (B) were assessed in cell lysates using qPCR and QuantiChrom™ assays, respectively, in CD15+CD14− granulocytic MDSCs after 48 h incubation with CpG-STAT3 siRNA, CpG-Luc siRNA or without any treatment. (C, D) Selective STAT3 inhibition alleviates immunosuppressive effect of MDSCs to greater extent than arginase inhibitor (nor-NOHA). Representative data from one of two experiments (C) and the summary of T cell proliferation assays (D) co-cultured in the presence or absence of MDSCs, nor-NOHA (20μM) and the indicated CpG-siRNAs (500 nM). Shown are means ± SD (n = 5). Statistically significant differences were indicated by asterisks.